Vertex Is Worth Your Attention - April 03, 2024

The company's promising pipeline holds several catalysts in reserve outperformance in 2024

• Learn about the growing biotech company known for its cystic fibrosis medications.
• Vertex Pharmaceuticals made history with the first gene-editing therapy based on a Nobel-prize winning technology called CRISPR and it has some more potential to uncover.
• The market has valued the company accordingly, but be ready when the buying window opens.

Conclusion

Investors may be nervous about the company's impressive past performance, with the stock advancing a compounded annual average of 20.20% for the last 10 years and 43.50% in the last year alone. This analysis has found Vertex has solid financials (high cash, low liabilities and impressive net margin) and a valid moat in the form of patent-protected intellectual property.

These parameters alone should only account for a part of the value attributed to Vertex Pharmaceuticals since the potential for its pipeline is tangible. The VX-548 pain-killer has the potential to efficaciously address the devastating opioid crisis with massive rewards coming along the way. All in all, it is a company worth paying attention to.